These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T; Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071 [TBL] [Abstract][Full Text] [Related]
3. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Park SK; Kim JH; Kang H; Cho JS; Smego RA Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342 [TBL] [Abstract][Full Text] [Related]
4. Extensively drug-resistant tuberculosis: current challenges and threats. Jain A; Mondal R FEMS Immunol Med Microbiol; 2008 Jul; 53(2):145-50. PubMed ID: 18479439 [TBL] [Abstract][Full Text] [Related]
6. Extensively drug-resistant Mycobacterium tuberculosis: Charles Darwin would understand. Iseman MD Clin Infect Dis; 2007 Dec; 45(11):1415-6. PubMed ID: 17990221 [No Abstract] [Full Text] [Related]
7. Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination. Koenig R Science; 2008 Feb; 319(5865):894-7. PubMed ID: 18276863 [No Abstract] [Full Text] [Related]
8. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Ramachandran R; Nalini S; Chandrasekar V; Dave PV; Sanghvi AS; Wares F; Paramasivan CN; Narayanan PR; Sahu S; Parmar M; Chadha S; Dewan P; Chauhan LS Int J Tuberc Lung Dis; 2009 Sep; 13(9):1154-60. PubMed ID: 19723407 [TBL] [Abstract][Full Text] [Related]
9. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan. Lai CC; Tan CK; Huang YT; Chou CH; Hung CC; Yang PC; Luh KT; Hsueh PR Clin Infect Dis; 2008 Oct; 47(7):e57-63. PubMed ID: 18715157 [TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154 [TBL] [Abstract][Full Text] [Related]
11. Trench warfare in a battle with TB. Marshall E Science; 2008 Jul; 321(5887):362-4. PubMed ID: 18635790 [No Abstract] [Full Text] [Related]
12. South Africa AIDS activist urges new TB plan. Clin Infect Dis; 2008 Jan; 46(1):iii; discussion iv. PubMed ID: 18181274 [No Abstract] [Full Text] [Related]
13. Can studies of the early bactericidal activity of rifapentine tell us how to prevent acquired rifamycin-resistant relapse? Wallis RS Am J Respir Crit Care Med; 2005 Jul; 172(1):4-5. PubMed ID: 15980108 [No Abstract] [Full Text] [Related]
14. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance. Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897 [TBL] [Abstract][Full Text] [Related]
15. Drug resistance profile of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Jos, Nigeria. Ani AE; Idoko J; Dalyop YB; Pitmang SL Trans R Soc Trop Med Hyg; 2009 Jan; 103(1):67-71. PubMed ID: 18789463 [TBL] [Abstract][Full Text] [Related]
16. [Fast identification of rifampicin-and isoniazid resistance of M. Tuberculosis strains by the "TB-biochip" test system]. Isakova ZhT Georgian Med News; 2008 May; (158):15-9. PubMed ID: 18560033 [TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. Bonora S; Mondo A; Trentini L; Calcagno A; Lucchini A; Di Perri G J Infect; 2008 Jul; 57(1):78-81. PubMed ID: 18550175 [TBL] [Abstract][Full Text] [Related]
18. The evolution of drug resistance in Mycobacterium tuberculosis: from a mono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population. Bifani P; Mathema B; Kurepina N; Shashkina E; Bertout J; Blanchis AS; Moghazeh S; Driscoll J; Gicquel B; Frothingham R; Kreiswirth BN J Infect Dis; 2008 Jul; 198(1):90-4. PubMed ID: 18498237 [TBL] [Abstract][Full Text] [Related]
19. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB). Martins M; Viveiros M; Ramos J; Couto I; Molnar J; Boeree M; Amaral L Int J Antimicrob Agents; 2009 May; 33(5):479-82. PubMed ID: 19155160 [TBL] [Abstract][Full Text] [Related]
20. Activity of the spiropiperidyl rifamycin LM 427 on rifampicin resistant Mycobacterium tuberculosis. Ungheri D; Della Bruna C; Sanfilippo A G Ital Chemioter; 1984; 31(3):211-4. PubMed ID: 6100178 [No Abstract] [Full Text] [Related] [Next] [New Search]